Melanoma Vaccine Trial Shows 12.2-Point Recurrence-Free Survival Gain
In 1,137 adults, personalized mRNA vaccine intismeran autogene plus Keytruda produced 82.2% two-year recurrence-free survival after melanoma surgery, versus 70% with placebo plus Keytruda.